BioWorld

Feb. 18, 2005

View Archived Issues

Dendreon Shows Survival Benefit In Phase III Study Of Provenge

A month after reporting a miss in a Phase III trial of its prostate cancer drug Provenge, Dendreon Corp. rebounded with data from the study showing a statistical improvement in patient survival rate. (BioWorld Today) Read More

FDA Doctor Questions Need For Any Drugs From the COX-2 Class

Read More

'Matchmaker' SNP Study Paves Way For Pharmacogenomics

Read More

BioCryst Raises $23.9M Privately To Fund Lead Clinical Products

Read More

Holiday Notice

Read More

Other News To Note

Read More